Stock MDGL MADRIGAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Madrigal Pharmaceuticals, Inc. Share Price

Equities

MDGL

US5588681057

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
193.3 USD -0.54% Intraday chart for Madrigal Pharmaceuticals, Inc. -8.82% -16.44%
22/04 BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
22/04 BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT

Financials

Sales 2024 * 81.74M 6.82B Sales 2025 * 351M 29.31B Capitalization 4.06B 338B
Net income 2024 * -459M -38.27B Net income 2025 * -296M -24.68B EV / Sales 2024 * 48.5 x
Net cash position 2024 * 93.53M 7.8B Net Debt 2025 * 116M 9.69B EV / Sales 2025 * 11.9 x
P/E ratio 2024 *
-8.3 x
P/E ratio 2025 *
-13 x
Employees 376
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.04%
More Fundamentals * Assessed data

Chart Madrigal Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Madrigal Pharmaceuticals, Inc.

BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Says Rezdiffra Available in US MT
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis CI
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,832,335, According to a Recent SEC Filing MT
Evercore ISI Raises Price Target on Madrigal Pharmaceuticals to $405 From $325, Maintains Outperform Rating MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday MT
Madrigal Pharmaceuticals Prices $600 Million Public Offering MT
Madrigal Pharmaceuticals Starts $500 Million Public Offering MT
Madrigal plans $500 million fund raising to prepare for NASH drug launch RE
Madrigal commences $500 million public offering of common stock RE
More news

Latest transcript on Madrigal Pharmaceuticals, Inc.

Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. - Special Call
More transcripts

Analyst Recommendations on Madrigal Pharmaceuticals, Inc.

BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing MT
More recommendations

Press releases Madrigal Pharmaceuticals, Inc.

Nonalcoholic Steatohepatitis Market to Observe Impressive Growth During the Forecast Period | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly and Company, Madrigal Pharmaceuticals AQ
Madrigal Statement on the Passing of Dr. Stephen Harrison AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 AQ
6 Stocks Positioned to Soar as Investors Focus on MASH AQ
More press releases

News in other languages on Madrigal Pharmaceuticals, Inc.

EE.UU. - Valores a seguir en Wall Street (actualizado)
Madrigal Pharmaceuticals : Super Micro Computer, Madrigal, Tencent... les valeurs à suivre aujourd'hui à Wall Street -
Madrigal Pharmaceuticals : lève 600 millions de dollars pour le lancement de son Rezdiffra
Wall Street ouvre en baisse, les regards tournés vers la Fed
EE.UU. - Valores a seguir en Wall Street (actualizado)
More news

Quotes and Performance

1 day-0.54%
1 week-8.82%
Current month-27.60%
1 month-21.92%
3 months-14.44%
6 months+54.78%
Current year-16.44%
More quotes

Highs and lows

1 week
189.00
Extreme 189
225.66
1 month
189.00
Extreme 189
268.22
Current year
168.25
Extreme 168.2462
299.98
1 year
119.76
Extreme 119.7604
322.67
3 years
52.33
Extreme 52.33
322.67
5 years
52.33
Extreme 52.33
322.67
10 years
6.60
Extreme 6.6
325.98
More quotes

Managers and Directors - Madrigal Pharmaceuticals, Inc.

Managers TitleAgeSince
Edward Chiang FOU
 Founder - 01/11/01
William Sibold CEO
 Chief Executive Officer - 08/23/08
Rebecca Taub FOU
 Founder 71 01/16/01
Members of the board TitleAgeSince
Fred Bernard Craves FOU
 Founder 78 01/11/01
Julian Baker CHM
 Chairman 57 15/23/15
Ken Bate BRD
 Director/Board Member 73 22/16/22
More insiders

ETFs positioned on Madrigal Pharmaceuticals, Inc.

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
0.35% 0 M€ 0.00% -
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
0.08% 0 M€ 0.00% -
More ETFs positioned on Madrigal Pharmaceuticals, Inc.

Quotes

Date Price Change Volume
26/24/26 193.3 -0.54% 453,346
25/24/25 194.4 -5.02% 707,188
24/24/24 204.6 -6.29% 575,504
23/24/23 218.4 +2.29% 409,554
22/24/22 213.5 +0.68% 727,326

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
Biotechnology & Medical Research
Calendar
07/05/2024 - Q1 2024 Earnings Release
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
193.3 USD
Average target price
377.1 USD
Spread / Average Target
+95.04%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MADRIGAL PHARMACEUTICALS, INC. Stock Madrigal Pharmaceuticals, Inc.
-16.44% 4.06B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MDGL Stock